Summary Carcinomas of the exocrine pancreas respond poorly to most chemotherapy regimens. Recently continuous infusional 5-fluorouracil (200 mg m2day') with 3 weekly cisplatin (60 mg m ) and epirubicin (50 mg m-2) (the ECF regimen) has proven to be an active regimen in gastric and breast cancer and consequently worthy of further study in pancreatic cancer. Thirty-five patients were treated with the ECF regimen as above, of whom 29 were evaluable for response and 32 were evaluable for toxicity. 
Carcinoma of the exocrine pancreas is the fifth commonest cancer and the fourth commonest cause of cancer deaths in the UK (Williamson, 1988) . Conventional methods of treatment including surgery, radiotherapy and chemotherapy offer little hope of cure and the 5 year survival is reported as less than 1% with a median survival of 2.8 months (Cancer of the Pancreas Task Force Group, 1981) .
Cancer of the pancreas responds poorly to most singleagent chemotherapy regimens, with the best response rates occurring with 5-fluorouracil (5-FU) (21-26%) (Carter, 1975; Moertel, 1976) , ifosfamide (26%) (Bernard et al., 1986) and epirubicin (22%) (Wils et al., 1985) . Recently response rates of 21% (Wils et al., 1993) have been reported using cisplatin. Furthermore, the results of combination chemotherapy have also been disappointing, with objective response rates of only 10% using 5-FU with BCNU, (Kovach et al., 1974) , 10% with 5-FU and mitomycin C (Buroker et al., 1979) and 14% with either FAM (5-FU, doxorubicin, mitomycin-C) or SMF I (5-FU, streptozotocin, mitomycin C) (Oster et al., 1986) .
In patients with colorectal cancer (Lokich et al., 1989 ) and breast cancer (Anderson, 1993) higher response rates have been achieved when 5-FU is given as a continuous intravenous infusion rather than by intermittent bolus schedules. Moreover there is evidence that cisplatin and 5-FU have synergistic anti-neoplastic activity (Scanlon et al., 1986; Trave et al., 1985) . Continuous infusion of low-dose 5-FU with cisplatin and epirubicin (the ECF regimen) has been reported to be a highly active regimen in the management of breast cancer (Jones et al., 1994) and gastro-oesophageal cancer (Findlay et al., 1994) . Consequently we considered this regimen worthy of evaluation in the management of patients with inoperable carcinoma of the exocrine pancreas.
Patients and methods
All patients entered into this study had histologically or cytologically confirmed adenocarcinoma of the pancreas. Inoperability was determined either on the basis of clinical evaluation and radiological imaging, or by laparotomy and failed resection. Eligibility included at least one site of disease that was measurable bidimensionally, the ability to manage an indwelling (i.v.) catheter, and adequate haematological function (WBC 4x 109 1-l, platelets l00x 109 1-'). Patients who had received chemotherapy previously were not eligible, but patients who had received radiotherapy to individual sites of disease were eligible, although the irradiated site was considered non-evaluable for response. Patient performance status was assessed using the World Health Organization (WHO) criteria (Miller et al., 1981) and those patients with performance status < 2 were considered eligible for this study. All patients gave informed, verbal consent.
Intravenous access
All chemotherapy was given via a double-lumen indwelling Hickman catheter (Davol, Cranston, USA) placed in the subclavian vein via a subcutaneous tunnel (Stacey et al., 1991) . Prophylactic low-dose warfarin (1 mg day-') was administered to reduce the incidence of venous thrombosis associated with indwelling central venous catheters (Bern et al., 1990) , and continued for the duration of the treatment. On the day of insertion, prophylactic flucloxacillin 500 mg q.d.s. orally was started and continued for a total of 5 days. Subsequent infections of the exit site were treated with a course of appropriate antibiotic based on the microbiology. Venous thrombosis associated with the Hickman line was managed by removal of the line and full anticoagulation, which was continued throughout treatment. diarrhoea the 5-FU was discontinued until these symptoms had resolved and was restarted with a 25% dose reduction. The 5-FU was administered for a total of 15 weeks, and stopped the day after the last of the 3 weekly cisplatin and epirubicin injections.
The cisplatin was administered at a dose of 60 mg m-2 on day 1 of the treatment and then every 21 days for a total of 6 cycles. This was given with standard pre-and postchemotherapy hydration protocols with potassium and magnesium supplements. Dose adjustment criteria for cisplatin were based on glomerular filtration rate (GFR), which was estimated using 5"Cr- [EDTA] clearance or 24 h urinary creatinine clearance. If the GFR was greater than or equal to 60 ml min-1, full-dose cisplatin was given. If the GFR was 40-60 ml min-m, a 25% dose reduction was performed for the patients treated at the start of the study, although this was subsequently modified so that the mg dose of cisplatin equalled the GFR value in ml min-'. This modification also applied to patients with a pretreatment GFR of 40-60 ml min-' for the first dose of cisplatin. If the GFR was <40 ml min-', either pretreatment or during ECF chemotherapy, carboplatin was substituted for cisplatin, and the dose calculated using the formula devised by Calvert et al. (1989) .
Epirubicin (50 mg m-2) was given as an intravenous bolus every 3 weeks immediately before the cisplatin. All patients had a baseline electrocardiogram (ECG), and if this was abnormal or there was a past history of cardiac disease, a pretreatment echocardiogram was also performed. With myelosuppression (white cell count <3.0 x l09 1-', platelets < 100 x 109 -1') at the time of the next cycle, treatment was delayed for 1 week or until the myelosuppression had resolved. In the presence of a second episode of treatment delay due to myelosuppression or an episode of neutropenic sepsis, a 25% dose reduction of the epirubicin would be given on subsequent treatments. If the patient's bilirubin was significantly elevated, usually as a result of resolving biliary obstruction, then the epirubicin dose was reduced appropriately, although this would be subsequently increased if the liver function tests improved sufficiently.
Evaluation of response and toxicity Response evaluation was based on the WHO criteria (Miller et al., 1981) . Complete response was defined as the complete disappearance of all known disease for at least 4 weeks. Partial response was defined as a 50% or greater reduction in the sum of the products of the longest tumour diameter and its longest perpendicular for at least 4 weeks, in the absence of the appearance of a new lesion or progression in any existing lesion. No change was defined as < 50% reduction in the total tumour size or an increase of <25% in one or more lesions. Progressive disease was defined as an increase of >25% in one or more lesions, or the appearance of any new lesion. Following pretreatment evaluation, a computerised tomography (CT) scan was repeated after cycles 3 and 6. Patients were not routinely restaged during follow-up and as most did not have clinically assessable disease, the exact time of disease relapse or progression was not documented for most patients. Overall survival was taken to be the more relevant end point and was measured from the day of starting chemotherapy until the date of death. Survival was measured in days and compared using the chi-squared test after logrank analysis using the Clinstat program.
Chemotherapy toxicity was graded using the WHO criteria (Miller et al., 1981) . Plantar -palmer erythema was graded using the WHO skin criteria. For each patient the toxicity was recorded as the worst toxicity for all cycles. Central venous line complications, including thromboembolic events, were documented, as were treatment-related deaths. Neutropenic sepsis occurred with 6 of the 17 cycles and platelet support was also required in the nadir of 6 of these 17 cycles of chemotherapy. Platinum agents were omitted during the treatment for three patients because of renal impairment (two patients) and hearing loss (one).
Results

Patient characteristics
Nineteen patients had either a reduction (13 patients) or an interruption of the infusional 5-FU (18). Dose reductions were due mainly to gastrointestinal toxicity with or without reported neutropenic infections.
Survival
Survival data are summarised in Tables III, IV and V. The exact date of death was unknown in two patients who were lost to follow-up after completing chemotherapy; it is known that both have died. There was no significant difference in the survival of patients with a partial response compared with those with either stable disease or progressive disease, although the number of responses is small (n = 5). However, when patients with either stable disease (median survival 253 days) or partial response (median survival 253 days) are considered together, they have a significantly improved overall survival compared with patients who progressed during treatment (median survival 170 days; P=0.01). For the patients with stable disease or a partial response, there was on significant difference in overall survival for patients with locally advanced (n = 11) compared with metastatic disease (n = 11, P = 0.28). Furthermore, there was no significant difference in survival between patients with baseline performance status 0 (n = 10) and performance status 1 (n= 18) (P=0.51). Moreover, when patients with partial response and stable disease were analysed, there was no significant survival difference between these two groups on the basis of baseline performance status (P=0.44).
Discussion
Carcinoma of the pancreas is inoperable in most cases, and as the responses to radiotherapy and chemotherapy are so poor it is almost inevitably fatal. Nevertheless, previous studies have shown that palliative chemotherapy does improve overall survival compared with no treatment without impairing quality of life (Leonard et al., 1992; Mallinson et al., 1980; Palmer et al., 1994) . Consequently, attempts to devise new chemotherapy regimens with the aim of improving response rates and overall survival are justified.
The primary objective of the study was to evaluate the ECF regimen in pancreatic cancer, to assess the response rate, toxicity and patient survival, particularly in view of the activity of this regimen in gastro-oesophageal and breast cancers. The partial response rate in this *study (17.3%) remains low compared with the response rates observed for gastro-oesophageal (71%) (Findlay et al., 1994) Nevertheless, there was considerable toxicity with this regimen. There was one definite treatment-related death which compares with the 4.3% treatment-related death rate with ECF in gastro-oesophageal cancers (Findlay et al., 1994) . The cause of death in two other patients who died at home while undergoing treatment was unknown. The other five deaths that occurred during treatment were not thought to be treatment-related. A further seven patients discontinued chemotherapy because of unacceptable toxicity, and one because of persistent and recurrent Hickman line complications. Despite anticoagulation with 1 mg day-' warfarin there was a high (17%) incidence of venous thrombosis associated with the Hickman catheter in comparison with the other studies (breast 9%, gastrointestinal 4%). This likely to be because of the high incidence of hypercoaguable state that occurs in pancreatic carcinoma (Sack et al., 1977; Sproule et al., 1938) and we have since increased the daily warfarin to 2 mg in patients with pancreatic cancer on the ECF regimen to try to reduce the incidence of this complication. Moreover although fourteen (40%) patients received the six courses of ECF chemotherapy only two patients received all six cycles of ECF without a dose reduction or delay.
Thus, the ECF regimen can prolong survival in patients with locally advanced or metastatic carcinoma of the pancreas. In this group of patients the toxicity is considerably higher when compared with patients receiving the same chemotherapy for breast or gastrointestinal cancers and highlights the need for very careful patient selection in terms of who is likely to benefit. The search for more active and less toxic drugs continues, and perhaps emphasises the importance of randomised studies with the inclusion of a best supportive care arm so that an objective assessment of quality of life and survival can be made.
